Nichi-Iko Suffers After Plant Closure
Emphasizes Five-Point Quality Control Plan As Profit Plummets
Japan’s Nichi-Iko has reported operating profit that has plummeted by more than 95% in its latest financial year, as the firm suffered a forced shutdown of once of its Japanese plants and also recognized a substantial impairment linked to its US Sagent business.
You may also be interested in...
Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.
Japan’s Sawai has laid out its mid- and long-term ambitions in a new company business plan, spanning both its local and overseas operations.
Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.